Scholarlink

<p>Colorectal cancer (CRC) is a prevalent malignancy with high mortality. Neutrophil extracellular traps (NETs) are implicated in metastasis and chemotherapy resistance, making them potential biomarkers for prognosis and treatment response. We extracted NETs-related genes (NRGs) from neutrophil transcriptome data derived from in vitro-treated cells and used LASSO regression to construct a NETs risk score model. Then we validated it in multiple public CRC datasets. Serum citrullinated histone H3 (CitH3) levels were measured in 146 CRC patients and 49 healthy controls by enzyme-linked immunosorbent assay (ELISA) to evaluate diagnostic and prognostic utility, as well as chemotherapy response prediction. The model demonstrated robust prognostic performance (AUC = 0.745-0.762 for 1-5 year survival), with high-risk patients exhibiting significantly reduced survival (<i>p</i> &lt; 0.0001) and compromised treatment efficacy. CitH3 levels were markedly elevated in CRC patients, particularly in those with poor prognosis and chemotherapy resistance, suggesting diagnostic and predictive utility. This study establishes NETs-based risk scoring as an effective tool for CRC prognosis and treatment response prediction, while serum CitH3 emerges as a promising biomarker for diagnosis and monitoring.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neutrophil extracellular traps as biomarkers for predicting prognosis and chemotherapy response in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月23日

查看全文
  • Chen Wang,
  • Junxiong Chen,
  • Ziyin Song,
  • Kexin Lv,
  • Haiyan Dong,
  • Liumei Liang,
  • Jingdan Zhang,
  • Huanliang Liu,
  • Jianxia Li,
  • Xiangling Yang

摘要

Colorectal cancer (CRC) is a prevalent malignancy with high mortality. Neutrophil extracellular traps (NETs) are implicated in metastasis and chemotherapy resistance, making them potential biomarkers for prognosis and treatment response. We extracted NETs-related genes (NRGs) from neutrophil transcriptome data derived from in vitro-treated cells and used LASSO regression to construct a NETs risk score model. Then we validated it in multiple public CRC datasets. Serum citrullinated histone H3 (CitH3) levels were measured in 146 CRC patients and 49 healthy controls by enzyme-linked immunosorbent assay (ELISA) to evaluate diagnostic and prognostic utility, as well as chemotherapy response prediction. The model demonstrated robust prognostic performance (AUC = 0.745-0.762 for 1-5 year survival), with high-risk patients exhibiting significantly reduced survival (p < 0.0001) and compromised treatment efficacy. CitH3 levels were markedly elevated in CRC patients, particularly in those with poor prognosis and chemotherapy resistance, suggesting diagnostic and predictive utility. This study establishes NETs-based risk scoring as an effective tool for CRC prognosis and treatment response prediction, while serum CitH3 emerges as a promising biomarker for diagnosis and monitoring.